| 5.35 -0.19 (-3.43%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.2 | 1-year : | 8.8 |
| Resists | First : | 6.17 | Second : | 7.53 |
| Pivot price | 5.9  |
|||
| Supports | First : | 3.96 | Second : | 3.29 |
| MAs | MA(5) : | 5.52  |
MA(20) : | 5.55 |
| MA(100) : | 7.35 |
MA(250) : | 8.02 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 33.7 |
D(3) : | 35.5 |
| RSI | RSI(14): 41.5 |
|||
| 52-week | High : | 12.35 | Low : | 3.96 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AEZS ] has closed above bottom band by 27.6%. Bollinger Bands are 18.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.48 - 5.51 | 5.51 - 5.54 |
| Low: | 5.28 - 5.31 | 5.31 - 5.34 |
| Close: | 5.3 - 5.36 | 5.36 - 5.4 |
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Tue, 16 Jul 2024
Aeterna Zentaris Announces Results of Virtual 2024 Meeting of Shareholders - StockTitan
Wed, 10 Jul 2024
Aeterna Zentaris (TSE:AEZS) Trading Up 34.5% - Defense World
Thu, 13 Jun 2024
Aeterna Zentaris completes key pediatric study - Investing.com
Mon, 03 Jun 2024
Aeterna Zentaris and Ceapro complete all-stock merger - Investing.com
Wed, 29 May 2024
Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 1.12e+006 (%) |
| Held by Institutions | 1.5 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.989e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -152 % |
| Return on Assets (ttm) | 750 % |
| Return on Equity (ttm) | -30 % |
| Qtrly Rev. Growth | 2.37e+006 % |
| Gross Profit (p.s.) | -46.21 |
| Sales Per Share | -37.83 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -2.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.15 |
| Price to Cash Flow | 1.08 |
| Dividend | 0 |
| Forward Dividend | 9300 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|